Rapport prÃ©liminaire d'analyses statistiques

Axelle Dupont, sbim, HÃ´pital Saint Louis, Paris

29 Mai 2017

Contents

List of Tables

List of Figures

1 Objectives

The primary objective of the study was to assess the survival, the risk of relapse and GVHD of patients who underwent allogenic sterm-cell transplantation (alloSCT) for aggressive T-cell lymphomas. The second objective was to determine the variables associated with these outcomes.

2 Methods

A retrospective analysis was conducted.A descriptive analysis of the variables recorded was perfomed. Different endpoints were defined : death, relapse ,Event-free survival(EFS) and Treatment related mortality (TRM).

Survival curves were estimated using Kaplan-Meier product-limit estimator. Factors associated with overall sur-vival were analyzed using Cox proportional hazards models. The proportional hazards assumption was checked by examination of Schoenfeld residuals. For the different endpoints, univariable analyses were first carried out, then a multivariable analysis was used where all factors with P-value < 0.15 in the univariable analyses were considered. Factors where then sequentially removed from the adjusted model with a P-value cut- at 0.05. Survival is presented as estimate and 95% confidence interval (95% CI).

Competing risk survival analysis methods were applied to estimate the cumulative incidence (CIF) of developing events over time from alloSCT.These methods allow for the fact that a patient may experience an event which is different from that of interest. These events are known as competing risk events, and may preclude the onset of the event of interest, or may modify the probability of the onset of that event. In particular, a transplanted patient may die before a relapse occurs. To test CIF between histopathologic groups we the test proposed by Gray.

3 Results

3.1 Descriptive results

Variables	n	%
$\leq$ 12 months betwenn diagnosis and allo SCT: 0	151	52.8
$\leq$ 12 months betwenn diagnosis and allo SCT: 1	135	47.2
$\leq$ 12 months betwenn diagnosis and allo SCT: NA	0	-
Histopathologic subtypes: AITL	84	29.4
Histopathologic subtypes: ALCL ALK-	20	7
Histopathologic subtypes: ALCL ALK?	2	0.7
Histopathologic subtypes: ALCL ALK+	21	7.3
Histopathologic subtypes: ATLL	16	5.6
Histopathologic subtypes: EATL	3	1
Histopathologic subtypes: HS	12	4.2
Histopathologic subtypes: LGL	1	0.3
Histopathologic subtypes: NK leukemia	1	0.3
Histopathologic subtypes: NK/T nasal	16	5.6
Histopathologic subtypes: NOS	110	38.5
Histopathologic subtypes: NA	0	-
Stage at diagnostic: I	13	6.4
Stage at diagnostic: II	17	8.4
Stage at diagnostic: III	45	22.2
Stage at diagnostic: IV	128	63.1
Stage at diagnostic: NA	83	-
disease status at transplant: CR	177	62.1
disease status at transplant: PD	32	11.2
disease status at transplant: PR	76	26.7
disease status at transplant: NA	1	-
disease status at transplant: CR (?)	7	2.5
disease status at transplant: CR1	94	33
disease status at transplant: CR2	63	22.1
disease status at transplant: CR3	13	4.6
disease status at transplant: PD	32	11.2
disease status at transplant: PR (?)	13	4.6
disease status at transplant: PR1	39	13.7
disease status at transplant: PR2	18	6.3
disease status at transplant: PR3	5	1.8
disease status at transplant: PR4	1	0.4
disease status at transplant: NA	1	-
Karnofsky: 100	93	35.1
Karnofsky: 40	2	0.8
Karnofsky: 50	4	1.5

Karnofsky: 60	1	0.4
Karnofsky: 70	9	3.4
Karnofsky: 80	70	26.4
Karnofsky: 90	86	32.5
Karnofsky: NA	21	-
previous autoSCT: 0	193	67.5
previous autoSCT: 1	93	32.5
previous autoSCT: NA	0	-
program autoallo: 0	259	90.6
program autoallo: 1	27	9.4
program autoallo: NA	0	-
relapse first graft: 0	220	76.9
relapse first graft: 1	65	22.7
relapse first graft: 2	1	0.3
relapse first graft: NA	0	-
No of lines before alloSCT: >2	89	34.8
No of lines before alloSCT: 1 or 2	167	65.2
No of lines before alloSCT: NA	30	-
Donnor related: 0	151	52.8
Donnor related: 1	135	47.2
Donnor related: NA	0	-
HLA match: 1	233	81.5
HLA match: 0	53	18.5
HLA match: NA	0	-
HLA match: Identical sibling	128	44.8
HLA match: Matched unrelated	105	36.7
HLA match: Mismatched relative	7	2.4
HLA match: Mismatched unrelated	13	4.5
HLA match: Unrelated CB	33	11.5
HLA match: NA	0	-
sex of patient/donnor: F/F	39	13.9
sex of patient/donnor: F/F/F	4	1.4
sex of patient/donnor: F/M	70	24.9
sex of patient/donnor: F/M/F	2	0.7
sex of patient/donnor: M/F	47	16.7
sex of patient/donnor: M/F/F	1	0.4
sex of patient/donnor: M/F/M	4	1.4
sex of patient/donnor: M/M	112	39.9
sex of patient/donnor: M/M/M	2	0.7
sex of patient/donnor: NA	5	-
CMV serostatus of patient/donnor: neg/neg	93	33
CMV serostatus of patient/donnor: neg/pos	52	18.4
CMV serostatus of patient/donnor: neg/pos/pos	2	0.7

CMV serostatus of patient/donnor: pos/neg	48	17
CMV serostatus of patient/donnor: pos/neg/neg	2	0.7
CMV serostatus of patient/donnor: pos/neg/pos	3	1.1
CMV serostatus of patient/donnor: pos/pos	80	28.4
CMV serostatus of patient/donnor: pos/pos/pos	2	0.7
CMV serostatus of patient/donnor: NA	4	-
Source of stem cells: BM	49	17.1
Source of stem cells: CB	33	11.5
Source of stem cells: PB	204	71.3
Source of stem cells: NA	0	-
tbi: No	162	56.6
tbi: Yes	124	43.4
tbi: NA	0	-
conditioning intensity: MAC	107	38.2
conditioning intensity: NMA	27	9.6
conditioning intensity: RIC	146	52.1
conditioning intensity: NA	6	-
conditioning: BEAM	1	0.4
conditioning: BEAM + Campath	1	0.4
conditioning: BU CY	4	1.4
conditioning: BU CY + FLU+ ATG	1	0.4
conditioning: BU CY ATG	1	0.4
conditioning: EDX ATG	1	0.4
conditioning: ENX TBI 2gray	1	0.4
conditioning: FLU ATG	3	1.1
conditioning: FLU BU 1+ ATG	3	1.1
conditioning: FLU BU 2	1	0.4
conditioning: FLU BU 2+ ATG	73	25.8
conditioning: FLU BU 3+ ATG	21	7.4
conditioning: FLU BU 4+ ATG	10	3.5
conditioning: FLU BU EDX	8	2.8
conditioning: FLU BU EDX +ATG	6	2.1
conditioning: FLU EDX	1	0.4
conditioning: FLU EDX ATG	3	1.1
conditioning: FLU EDX MEL	1	0.4
conditioning: FLU ENX TBI 2gray	24	8.5
conditioning: FLU ENX TBI 4gray	2	0.7
conditioning: FLU ENX TBI 6gray	1	0.4
conditioning: FLU ENX TBI 6gray + campath	1	0.4
conditioning: FLU MEL	12	4.2
conditioning: FLU MEL + campath	4	1.4
conditioning: FLU MEL + Campath	1	0.4
conditioning: FLU MEL ATG	1	0.4

conditioning: FLU MEL TBI 2gray	1	0.4
conditioning: FLU TBI 2gray	21	7.4
conditioning: FLU TBI 2gray ATG	1	0.4
conditioning: FLU Tbi 8 gray	1	0.4
conditioning: MEL 140 TBI 10 gray	1	0.4
conditioning: MEL TBI VP16	1	0.4
conditioning: TB2F	2	0.7
conditioning: TBI 12 gray	1	0.4
conditioning: TBI 2gray	1	0.4
conditioning: TBI EDX	49	17.3
conditioning: TBI EDX +ATG	12	4.2
conditioning: TBI EDX FLU	5	1.8
conditioning: Thiotepa etoposide TBI12 gray	1	0.4
conditioning: NA	3	-
cells manipulation: none	277	97.9
cells manipulation: yes	6	2.1
cells manipulation: NA	3	-
no of donnors: 1	263	92
no of donnors: 2	23	8
no of donnors: NA	0	-
agvhd: 0	142	49.7
agvhd: 1	144	50.3
agvhd: NA	0	-
agvhd grade: No aGvHD present (Grade 0)	142	49.7
agvhd grade: Grade I	50	17.5
agvhd grade: Grade II	46	16.1
agvhd grade: Grade III	24	8.4
agvhd grade: Grade IV	17	5.9
agvhd grade: Present, grade unknown	7	2.4
agvhd grade: NA	0	-
cgvhd: 0	189	66.1
cgvhd: 1	97	33.9
cgvhd: NA	0	-
cgvhd grade: deces avant J100	43	15
cgvhd grade: extensive	38	13.3
cgvhd grade: limited	55	19.2
cgvhd grade: no cGvh	146	51
cgvhd grade: unknown	4	1.4
cgvhd grade: NA	0	-
Cause of death: HSCT-GVHd	21	19.3
Cause of death: HSCT-GVHd + infection	3	2.8
Cause of death: HSCT-infection	29	26.6
Cause of death: HSCT-toxicitÃ©	4	3.7

Cause of death: HSCT related	3	2.8
Cause of death: HSCT related MAT	1	0.9
Cause of death: HSCT related MOF	2	1.8
Cause of death: HSCT related MVO	1	0.9
Cause of death: HSCT related pneumopathie interstititelle	3	2.8
Cause of death: HSCT related PTLD	1	0.9
Cause of death: HSCT related SDRA	1	0.9
Cause of death: Other	1	0.9
Cause of death: relapse or progression of original disease	37	33.9
Cause of death: Secondary malignancy	1	0.9
Cause of death: unknown	1	0.9
Cause of death: NA	177	-
Best reponse after SCT: cr	247	87
Best reponse after SCT: Not evaluable	4	1.4
Best reponse after SCT: Not evaluated	3	1.1
Best reponse after SCT: PD	14	4.9
Best reponse after SCT: PR	16	5.6
Best reponse after SCT: NA	2	-
Relapse/progression: continuous progression	28	9.9
Relapse/progression: No	219	77.1
Relapse/progression: Non applicable	3	1.1
Relapse/progression: yes	34	12
Relapse/progression: NA	2	-

Table 1: Transplant condition and results

3.2 Results by histopathologic subtypes

Parameters	Values	Subtypes												NA
		N	Statistics*	N	Statistics*	N	Statistics*	N	Statistics*	N	Statistics*	N	Statistics*	p-value
		110	NOS	84	AITL	43	ALCL	16	ATLL	16	NK/T nasal	17	Others	
Age at diagnostic		110	48.5 [38;55]	84	53 [43;57.25]	43	36 [23;49]	16	41 [30.75;45.5]	16	39.5 [34.75;48]	17	38 [33;45]	0.0001
Patient sex	Female	33	30 %	27	32.14 %	17	39.53 %	5	31.25 %	4	25 %	9	52.94 %	0.45
	Male	77	70 %	57	67.86 %	26	60.47 %	11	68.75 %	12	75 %	8	47.06 %	

Table 2: Patients characteristics

Parameters	Values							Subtypes	
		N	Statistics*	N	Statistics*	N	Statistics*	N	Statisti
		110	NOS	84	AITL	43	ALCL	16	ATLL
Age at graft		110	51 [39;57]	84	54 [45;60]	43	38 [25;52.5]	16	42 [31.5
Age at graft	< 49 years	50	45.45 %	28	33.33 %	29	67.44 %	12	75 %
	> 49 years	60	54.55 %	56	66.67 %	14	32.56 %	4	25 %
Donor age		103	29 [17;40.5]	77	26 [16;35]	38	27 [17.25;33.75]	16	33.5 [22
Donor sex	Female	48	44.44 %	38	45.24 %	15	34.88 %	4	26.67 %
	Male	60	55.56 %	46	54.76 %	28	65.12 %	11	73.33 %
	NA	2		0		0		1	
>12 months betwenn diagnosis and allo SCT	0	56	50.91 %	47	55.95 %	22	51.16 %	10	62.5 %
	1	54	49.09 %	37	44.05 %	21	48.84 %	6	37.5 %
Stage at diagnostic	I	5	6.76 %	0	0 %	2	6.45 %	0	0 %
	II	7	9.46 %	5	7.94 %	4	12.9 %	0	0 %
	III	15	20.27 %	21	33.33 %	8	25.81 %	1	11.11 %
	IV	47	63.51 %	37	58.73 %	17	54.84 %	8	88.89 %
	NA	36		21		12		7	
Stage at diagnostic	I-II	48	43.64 %	26	30.95 %	18	41.86 %	7	43.75 %
	III-IV	62	56.36 %	58	69.05 %	25	58.14 %	9	56.25 %

Disease status at transplant	CR/PR	97	88.18 %	75	89.29 %	37	88.1 %	13	81.25 %
	PD	13	11.82 %	9	10.71 %	5	11.9 %	3	18.75 %
	NA	0		0		1		0	
Disease status at transplant	CR	67	60.91 %	57	67.86 %	28	66.67 %	7	43.75 %
	PD	13	11.82 %	9	10.71 %	5	11.9 %	3	18.75 %
	PR	30	27.27 %	18	21.43 %	9	21.43 %	6	37.5 %
	NA	0		0		1		0	
Disease status at transplant	CR (?)	4	3.64 %	2	2.38 %	0	0 %	0	0 %
	CR1	36	32.73 %	28	33.33 %	13	30.95 %	6	37.5 %
	CR2	23	20.91 %	23	27.38 %	10	23.81 %	1	6.25 %
	CR3	4	3.64 %	4	4.76 %	5	11.9 %	0	0 %
	PD	13	11.82 %	9	10.71 %	5	11.9 %	3	18.75 %
	PR (?)	7	6.36 %	5	5.95 %	0	0 %	1	6.25 %
	PR1	16	14.55 %	8	9.52 %	5	11.9 %	2	12.5 %
	PR2	6	5.45 %	3	3.57 %	2	4.76 %	3	18.75 %
	PR3	1	0.91 %	2	2.38 %	1	2.38 %	0	0 %
	PR4	0	0 %	0	0 %	1	2.38 %	0	0 %
	NA	0		0		1		0	
Karnofsky	100	39	37.5 %	29	37.18 %	16	41.03 %	3	21.43 %
	40	0	0 %	2	2.56 %	0	0 %	0	0 %
	50	4	3.85 %	0	0 %	0	0 %	0	0 %
	60	1	0.96 %	0	0 %	0	0 %	0	0 %
	70	2	1.92 %	4	5.13 %	1	2.56 %	0	0 %
	80	22	21.15 %	26	33.33 %	5	12.82 %	4	28.57 %
	90	36	34.62 %	17	21.79 %	17	43.59 %	7	50 %
	NA	6		6		4		2	
Karnofsky	Normal activities with or without efforts	97	88.18 %	72	85.71 %	38	88.37 %	14	87.5 %
	Unable to carry on normal activity	13	11.82 %	12	14.29 %	5	11.63 %	2	12.5 %
previous autoSCT	0	72	65.45 %	57	67.86 %	25	58.14 %	15	93.75 %
	1	38	34.55 %	27	32.14 %	18	41.86 %	1	6.25 %

program autoallo	0	98	89.09 %	79	94.05 %	37	86.05 %	16	100 %
	1	12	10.91 %	5	5.95 %	6	13.95 %	0	0 %
relapse first graft	0	84	76.36 %	62	73.81 %	31	72.09 %	15	93.75 %
	1	26	23.64 %	21	25 %	12	27.91 %	1	6.25 %
	2	0	0 %	1	1.19 %	0	0 %	0	0 %
No of lines before alloSCT	1	31	32.63 %	20	25.64 %	11	28.95 %	2	14.29 %
	2	30	31.58 %	30	38.46 %	10	26.32 %	8	57.14 %
	3	26	27.37 %	20	25.64 %	10	26.32 %	4	28.57 %
	4	8	8.42 %	8	10.26 %	7	18.42 %	0	0 %
	NA	15		6		5		2	
Donnor related	0	61	55.45 %	45	53.57 %	22	51.16 %	8	50 %
	1	49	44.55 %	39	46.43 %	21	48.84 %	8	50 %
HLA match	1	85	77.27 %	77	91.67 %	35	81.4 %	9	56.25 %
	0	25	22.73 %	7	8.33 %	8	18.6 %	7	43.75 %
HLA match	Identical sibling	46	41.82 %	38	45.24 %	18	41.86 %	8	50 %
	Matched unrelated	39	35.45 %	39	46.43 %	17	39.53 %	1	6.25 %
	Mismatched relative	3	2.73 %	1	1.19 %	3	6.98 %	0	0 %
	Mismatched unrelated	7	6.36 %	3	3.57 %	2	4.65 %	1	6.25 %
	Unrelated CB	15	13.64 %	3	3.57 %	3	6.98 %	6	37.5 %
sex of patient/donnor	M/F	16	14.55 %	12	14.29 %	10	23.26 %	2	12.5 %
	Others	94	85.45 %	72	85.71 %	33	76.74 %	14	87.5 %
CMV serostatus of patient/donnor	autres	91	82.73 %	69	82.14 %	37	86.05 %	13	81.25 %
	neg/pos	19	17.27 %	15	17.86 %	6	13.95 %	3	18.75 %
Source of stem cells	BM	20	18.18 %	13	15.48 %	7	16.28 %	2	12.5 %
	CB	15	13.64 %	3	3.57 %	3	6.98 %	6	37.5 %
	PB	75	68.18 %	68	80.95 %	33	76.74 %	8	50 %
tbi	No	61	55.45 %	54	64.29 %	26	60.47 %	5	31.25 %
	Yes	49	44.55 %	30	35.71 %	17	39.53 %	11	68.75 %

Table 3: Transplant conditions

Parameters	Values	Subtypes										
		N	Statistics*	N	Statistics*	N	Statistics*	N	Statistics*	N	Statistics*	N
		110	NOS	84	AITL	43	ALCL	16	ATLL	16	NK/T nasal	1
conditioning intensity	MAC	47	43.93 %	21	25.3 %	14	33.33 %	8	50 %	7	46.67 %	1
	NMA	8	7.48 %	13	15.66 %	3	7.14 %	1	6.25 %	1	6.67 %	1
	RIC	52	48.6 %	49	59.04 %	25	59.52 %	7	43.75 %	7	46.67 %	6
	NA	3		1		1		0		1		0
conditioning	BEAM	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	BEAM + Campath	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	BU CY	1	0.92 %	0	0 %	2	4.65 %	0	0 %	1	6.67 %	0
	BU CY + FLU+ ATG	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	BU CY ATG	0	0 %	1	1.2 %	0	0 %	0	0 %	0	0 %	0
	EDX ATG	0	0 %	1	1.2 %	0	0 %	0	0 %	0	0 %	0
	ENX TBI 2gray	0	0 %	1	1.2 %	0	0 %	0	0 %	0	0 %	0
	FLU ATG	0	0 %	1	1.2 %	2	4.65 %	0	0 %	0	0 %	0
	FLU BU 1+ ATG	1	0.92 %	2	2.41 %	0	0 %	0	0 %	0	0 %	0
	FLU BU 2	0	0 %	1	1.2 %	0	0 %	0	0 %	0	0 %	0
	FLU BU 2+ ATG	25	22.94 %	24	28.92 %	14	32.56 %	3	18.75 %	4	26.67 %	3
	FLU BU 3+ ATG	13	11.93 %	4	4.82 %	3	6.98 %	0	0 %	0	0 %	1
	FLU BU 4+ ATG	4	3.67 %	2	2.41 %	1	2.33 %	1	6.25 %	2	13.33 %	0
	FLU BU EDX	4	3.67 %	4	4.82 %	0	0 %	0	0 %	0	0 %	0
	FLU BU EDX +ATG	1	0.92 %	4	4.82 %	0	0 %	0	0 %	0	0 %	1
	FLU EDX	0	0 %	1	1.2 %	0	0 %	0	0 %	0	0 %	0
	FLU EDX ATG	1	0.92 %	1	1.2 %	0	0 %	0	0 %	1	6.67 %	0
	FLU EDX MEL	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	FLU ENX TBI 2gray	13	11.93 %	3	3.61 %	5	11.63 %	2	12.5 %	1	6.67 %	0
	FLU ENX TBI 4gray	1	0.92 %	1	1.2 %	0	0 %	0	0 %	0	0 %	0
	FLU ENX TBI 6gray	0	0 %	0	0 %	0	0 %	0	0 %	1	6.67 %	0
	FLU ENX TBI 6gray + campath	0	0 %	0	0 %	0	0 %	1	6.25 %	0	0 %	0
	FLU MEL	4	3.67 %	3	3.61 %	3	6.98 %	1	6.25 %	0	0 %	1

	FLU MEL + campath	1	0.92 %	2	2.41 %	1	2.33 %	0	0 %	0	0 %	0
	FLU MEL + Campath	0	0 %	0	0 %	0	0 %	0	0 %	0	0 %	1
	FLU MEL ATG	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	FLU MEL TBI 2gray	0	0 %	0	0 %	0	0 %	0	0 %	1	6.67 %	0
	FLU TBI 2gray	5	4.59 %	11	13.25 %	3	6.98 %	1	6.25 %	0	0 %	1
	FLU TBI 2gray ATG	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	FLU Tbi 8 gray	0	0 %	0	0 %	0	0 %	0	0 %	0	0 %	1
	MEL 140 TBI 10 gray	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	MEL TBI VP16	0	0 %	0	0 %	1	2.33 %	0	0 %	0	0 %	0
	TB2F	0	0 %	2	2.41 %	0	0 %	0	0 %	0	0 %	0
	TBI 12 gray	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	TBI 2gray	1	0.92 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	TBI EDX	20	18.35 %	12	14.46 %	5	11.63 %	3	18.75 %	2	13.33 %	7
	TBI EDX +ATG	5	4.59 %	2	2.41 %	1	2.33 %	3	18.75 %	0	0 %	1
	TBI EDX FLU	1	0.92 %	0	0 %	1	2.33 %	1	6.25 %	2	13.33 %	0
	Thiotepa etoposide TBI12 gray	0	0 %	0	0 %	1	2.33 %	0	0 %	0	0 %	0
	NA	1		1		0		0		1		0
cells manipulation	none	105	97.22 %	82	97.62 %	43	100 %	15	100 %	15	93.75 %	1
	yes	3	2.78 %	2	2.38 %	0	0 %	0	0 %	1	6.25 %	0
	NA	2		0		0		1		0		0
no of donnors	1	99	90 %	81	96.43 %	42	97.67 %	12	75 %	13	81.25 %	1
	2	11	10 %	3	3.57 %	1	2.33 %	4	25 %	3	18.75 %	1
agvhd	0	56	50.91 %	43	51.19 %	24	55.81 %	6	37.5 %	8	50 %	5
	1	54	49.09 %	41	48.81 %	19	44.19 %	10	62.5 %	8	50 %	1
agvhd grade	No aGvHD present (Grade 0)	56	50.91 %	43	51.19 %	24	55.81 %	6	37.5 %	8	50 %	5
	Grade I	21	19.09 %	12	14.29 %	6	13.95 %	4	25 %	2	12.5 %	5
	Grade II	20	18.18 %	14	16.67 %	8	18.6 %	1	6.25 %	3	18.75 %	0
	Grade III	8	7.27 %	6	7.14 %	2	4.65 %	4	25 %	0	0 %	4
	Grade IV	2	1.82 %	6	7.14 %	3	6.98 %	1	6.25 %	3	18.75 %	2
	Present, grade unknown	3	2.73 %	3	3.57 %	0	0 %	0	0 %	0	0 %	1

cgvhd	0	70	63.64 %	52	61.9 %	30	69.77 %	13	81.25 %	13	81.25 %	1
	1	40	36.36 %	32	38.1 %	13	30.23 %	3	18.75 %	3	18.75 %	6
cgvhd grade	deces avant J100	14	12.73 %	15	17.86 %	5	11.63 %	2	12.5 %	3	18.75 %	4
	extensive	14	12.73 %	15	17.86 %	4	9.3 %	1	6.25 %	1	6.25 %	3
	limited	23	20.91 %	17	20.24 %	8	18.6 %	2	12.5 %	2	12.5 %	3
	no cGvh	56	50.91 %	37	44.05 %	25	58.14 %	11	68.75 %	10	62.5 %	7
	unknown	3	2.73 %	0	0 %	1	2.33 %	0	0 %	0	0 %	0
Engrafted	deces avant J30	1	0.91 %	2	2.38 %	1	2.33 %	0	0 %	1	6.25 %	0
	engrafted	109	99.09 %	80	95.24 %	41	95.35 %	13	81.25 %	13	81.25 %	1
	lost graft	0	0 %	0	0 %	1	2.33 %	1	6.25 %	0	0 %	0
	no engraftment	0	0 %	2	2.38 %	0	0 %	2	12.5 %	2	12.5 %	1
Cause of death	HSCT-GVHd	3	8.57 %	9	26.47 %	1	6.25 %	2	22.22 %	2	25 %	4
	HSCT-GVHd + infection	1	2.86 %	1	2.94 %	1	6.25 %	0	0 %	0	0 %	0
	HSCT-infection	6	17.14 %	13	38.24 %	6	37.5 %	1	11.11 %	1	12.5 %	2
	HSCT-toxicitÃ©	1	2.86 %	1	2.94 %	1	6.25 %	0	0 %	1	12.5 %	0
	HSCT related	1	2.86 %	2	5.88 %	0	0 %	0	0 %	0	0 %	0
	HSCT related MAT	1	2.86 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	HSCT related MOF	1	2.86 %	1	2.94 %	0	0 %	0	0 %	0	0 %	0
	HSCT related MVO	1	2.86 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	HSCT related pneumopathie interstititelle	2	5.71 %	1	2.94 %	0	0 %	0	0 %	0	0 %	0
	HSCT related PTLD	1	2.86 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	HSCT related SDRA	1	2.86 %	0	0 %	0	0 %	0	0 %	0	0 %	0
	Other	0	0 %	1	2.94 %	0	0 %	0	0 %	0	0 %	0
	relapse or progression of original disease	16	45.71 %	4	11.76 %	7	43.75 %	5	55.56 %	4	50 %	1
	Secondary malignancy	0	0 %	1	2.94 %	0	0 %	0	0 %	0	0 %	0
	unknown	0	0 %	0	0 %	0	0 %	1	11.11 %	0	0 %	0
	NA	75		50		27		7		8		1
best reponse after SCT	cr	93	85.32 %	75	89.29 %	39	90.7 %	12	75 %	15	93.75 %	1
	Not evaluable	1	0.92 %	2	2.38 %	0	0 %	0	0 %	0	0 %	1
	Not evaluated	0	0 %	1	1.19 %	1	2.33 %	1	6.25 %	0	0 %	0

	PD	6	5.5 %	2	2.38 %	2	4.65 %	2	12.5 %	0	0 %	2
	PR	9	8.26 %	4	4.76 %	1	2.33 %	1	6.25 %	1	6.25 %	0
	NA	1		0		0		0		0		1
Relapse/progression	continuous progression	14	12.73 %	5	6.02 %	3	7.14 %	3	18.75 %	1	6.25 %	2
	No	83	75.45 %	70	84.34 %	33	78.57 %	8	50 %	11	68.75 %	1
	Non applicable	0	0 %	1	1.2 %	0	0 %	1	6.25 %	0	0 %	1
	yes	13	11.82 %	7	8.43 %	6	14.29 %	4	25 %	4	25 %	0
	NA	0		1		1		0		0		0

Table 4: Transplant conditions (next)

3.3 Survival analysis



Figure 1: KM Overall survival